Multiple System Atrophy Market to Grow with a CAGR of 3.11% through 2028
The increasing in frequency of neurodegenerative
diseases is expected to drive the Global Multiple System Atrophy Market growth
in the forecast period, 2024-2028.
According to TechSci
Research report, “Multiple System Atrophy Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2028”, the
Global Multiple System Atrophy Market stood at USD 149.73 Million in 2022 and
is anticipated to grow with a CAGR of 3.11% through 2028. This disorder poses
significant threat to a patient's quality of life, obstructing their day-to-day
activities at large. MSA life expectancy may vary from person to person but on
an average a patient may live 6-9 years from the time of detection. It is crucial
to determine the MSA risk factors at an early stage so that professionals can
accurately formulate MSA coping strategies. Medical scientists and healthcare
professionals have expedited their MSA research & development activities
with an aim to facilitate effective drug development. The growing disease
burden is indeed pointing towards a global health hazard which needs to be
tackled effectively.
Major shy drager syndrome
symptoms include muscle stiffness, postural deformity, dizziness, orthostatic
hypotension, sexual dysfunction, bowel issues, slurred speech, behavioural
changes, and cognitive issues. MSA outcomes can be severe if the symptoms go
unnoticed.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Multiple System Atrophy Market”
The Global Multiple
System Atrophy Market is segmented into Diagnosis, Age, End
User and company.
Based on the
Diagnosis, the Magnetic Resonance Imaging segment is anticipated to witness
substantial market growth throughout the forecast period. Magnetic Resonance
Imaging (MRI) is poised to be a catalyst for the growth of the Global Multiple
System Atrophy (MSA) Market. As a non-invasive and advanced imaging technique,
MRI plays a pivotal role in the early and accurate diagnosis of MSA,
contributing to improved patient outcomes and streamlined clinical trials. MRI
enables the visualization of structural abnormalities and changes in the brain
associated with MSA, providing clinicians with valuable insights into the
disease's progression. This diagnostic precision is crucial for distinguishing
MSA from other neurodegenerative disorders and facilitating prompt
intervention. In addition to its diagnostic utility, MRI is becoming
increasingly instrumental in advancing MSA research and drug development. It
serves as a key tool for monitoring treatment efficacy and disease progression
in clinical trials, offering objective and quantifiable measures that enhance the
efficiency of these studies. The widespread adoption of MRI technology in both
clinical practice and research initiatives creates a synergistic effect,
fostering collaboration between healthcare institutions, pharmaceutical
companies, and imaging technology developers.
Based on the End
User segment, the Hospitals segment has been the dominant force in the market.
Hospitals are positioned as key drivers in fueling the growth of the Global
Multiple System Atrophy (MSA) Market. As primary hubs for healthcare delivery,
hospitals play a central role in the diagnosis, treatment, and management of
MSA. The rising prevalence of MSA, coupled with increasing awareness and
diagnostic capabilities, results in a growing number of patients seeking care
in hospital settings. Hospitals contribute significantly to the expansion of
the MSA market by serving as crucial centers for clinical trials and research
initiatives. These institutions often collaborate with pharmaceutical
companies, research organizations, and other stakeholders to conduct studies,
advancing our understanding of the disease and facilitating the development of
novel therapeutic interventions. Moreover, the demand for specialized MSA care
within hospital settings fosters the growth of dedicated neurology departments
and clinics. This specialization not only enhances patient outcomes but also
attracts investments in infrastructure, technology, and healthcare
professionals, creating a robust ecosystem for MSA-focused advancements.
Major companies operating
in Global Multiple System Atrophy Market are
- Biohaven Ltd.
- Theravance Biopharma
- Sumitomo Dainippon Pharma Co., Ltd.
- Alterity Therapeutics
- AstraZeneca plc.
- Biogen
- Merck & Co., Inc.
- Neuropore Therapies, Inc.
- WaveBreak Therapeutics
- Newron Pharmaceuticals SPA
Download Free Sample Report
Customers can
also request 10% free customization on this report
“The Global
Multiple System Atrophy (MSA) Market is propelled by several key drivers
shaping its growth trajectory. Firstly, increasing awareness and early
diagnosis initiatives have elevated patient identification, driving demand for
MSA therapeutics. Additionally, a surge in research and development activities
focused on novel treatment modalities and disease-modifying interventions has
fueled market expansion. The growing elderly population, particularly in
developed regions, contributes significantly to the rising prevalence of MSA,
bolstering market prospects. Furthermore, collaborative efforts between
pharmaceutical companies and research institutions enhance the development of
innovative therapies. Technological advancements in diagnostic tools and
biomarker identification also play a pivotal role in advancing MSA treatment
options. These collective factors create a conducive environment for sustained
market growth, fostering opportunities for stakeholders in the global MSA
market.” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Multiple
System Atrophy Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented By Diagnosis (Magnetic Resonance Imaging (MRI),
Positron Emission Tomography (PET), Single Photon Emission Computed Tomography
(SPECT), Tilt Table Test, Others), By Age (Pediatric, Adults, Geriatric), By
End User (Hospitals, Ambulatory Surgical Centers, Others), By Region, By
Competition”, has evaluated the future growth potential of Global
Multiple System Atrophy Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Multiple
System Atrophy Market.
Contact
TechSci Research
LLC
420 Lexington
Avenue, Suite 300,
New York, United
States- 10170
Tel:
+1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com